We are excited to announce that Nonacus are recruiting! Following the successful launch of our Cell3TM DNA product range we are now growing the team and are seeking a highly motivated experienced Quality Assurance (QA) / Quality Control (QC) Production Scientist to join our team. The full job description and details on how to apply can […]
There’s been a revolution. It comes in the form of cell free DNA (cfDNA), which is changing patient pathways for the better across the globe. Due to its nature, cfDNA is considered as an excellent biomarker and source of genetic information. Cell free DNA is thought to originate predominantly from cells that undergo programmed cell […]
Nonacus reviews latest accreditation efforts. Currently, the RhD genotyping landscape doesn’t feature a full EQA (European Quality Assurance) scheme but this latest report published in Blood Transfusion represents a big step forward towards an EQA. The authors have set themselves an objective to implement a regular EQA scheme through their working group. Chris Sale- CEO […]
New direct from plasma cfDNA test provides results in three hours. Since 2011 the NHS has been using cell free DNA (cfDNA) in fetal sex testing to identify pregnancies at high risk of sex-linked disorders. This test is done by extracting cfDNA from maternal plasma: a process that is slowing down results for patients. Nonacus […]
Find out how a leading NHS laboratory performed NIPD for fetal sexing directly from plasma using our proprietary Cell3TMDirect technology. Click here to view the poster.
Montpellier, Nonacus Ltd today announced the launch of a new DNA extraction kit designed to assist both researchers and clinicians translate the huge potential of circulating cell free DNA into improved patient care. Non-invasive screening of cell free DNA has already revolutionised the screening of conditions such as Down Syndrome in high risk pregnancies however […]
Nonacus is attending and sponsoring the 10th CNAPS International Symposium in Montpellier. Dr Michael Parks’ abstract has been accepted for an oral presentation: A direct from plasma approach to non-invasive prenatal fetal sex determination and RhesusD genotyping by quantitative PCR
Dr Michael Parks, previous recipient of the ESHG young investigator award, will be presenting a poster on our innovative Plasma Cell3TMDirect qPCR technology at the ESHG 2017 conference in Copenhagen:‘A direct from plasma approach to non-invasive prenatal fetal sex determination and RhesusD genotyping by quantitative PCR’(Control No. 2017-A-719-ESHG).
Nonacus is attending and sponsoring the 3rd International Meeting on Cell Free DNA conference in Copenhagen. Come and visit the team at booth H. Dr Michael Parks will be presenting our technology at the conference : A direct from plasma approach for non-invasive fetal RhesusD genotyping April 06, 2017, 16:10-16:45.
We are pleased to announce that we have moved into our new business premises and laboratory at the Birmingham BioHub. The facility offers purpose built state of the art laboratory and office space. The team are looking forward to getting to work and making the most of the new facilities.